UNSPSC 51434100: Antihypertensive quaternary ammonium compounds

Antihypertensive drugs made from derivatives of ammonium compounds, nh4+ y-, in which all four of the hydrogens bonded to nitrogen have been replaced with hydrocarbyl groups.

UNSPSC 51434100 Antihypertensive quaternary ammonium compounds is a Class code that encompasses emergency-response medications and life-support pharmaceuticals supplied to municipal fire and emergency medical services, as well as broader state-level pharmaceutical procurement serving public health systems and cooperative purchasing networks. State and local governments acquire these compounds — including labetalol, diltiazem, and related antihypertensive agents — as finished injectable products for emergency protocols, with vendors supplying units that meet strict expiration-date thresholds, OSHA Hazard Communication compliance, and warranty requirements for defect-free materials. The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body mix: municipal fire and emergency services departments, state health agencies, and regional cooperative purchasing organizations that aggregate demand across multiple state and local participants. Contracts typically include one-year or multi-year terms with renewal options, firm fixed pricing that includes freight and applicable taxes, and small-local-business-enterprise set-asides or preference programs where applicable.

Recent activity spans Florida, Texas, and a multi-state region administered through Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, to supply 370 units of labetalol HCl 100mg vials, 1,810 units of epinephrine 1:10,000 injections, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials to Tampa Fire Rescue, with an estimated contract value of $40,000 and a 5 percent bid discount for small local business enterprises. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state-level interest in alternative distribution models for pharmaceutical procurement. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (S1070000015802) due March 26, 2026, to establish multi-year contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and the remaining 25 percent on administrative compliance, pricing format options, and EDI capability. All three solicitations require vendors to maintain FDA compliance, cGMP certification where applicable, comprehensive insurance coverage, and compliance with federal drug-supply-chain security standards.